

ASX REPORT TO SHAREHOLDERS

## 9 September 2013

Red5Limited

is a publicly listed company on the ASX - ticker symbol RED

Inquiries regarding this report and company business may be directed to:

## **Steve Norregaard**

Managing Director (mob Aus) +61 448 395 012 (mob Phi) +63 9498 888 456

or

**Colin G. Jackson** *Chairman* (mob) +61 407 718 372

Investor Inquiries: info@red5limited.com

Address & Registered Office: Level 2, 35 Ventnor Avenue West Perth 6005 Western Australia Tel: (+61) 8 9322 4455 Fax: (+61) 8 9481 5950 Web: www.red5limited.com

## **Completion of share placement**

The directors of Red 5 Limited (**Red 5** or **Company**) advise that the proposed private placement announced on 5 September 2013 has been successfully concluded, with final commitments received for a total of \$50,000,000, comprising 500,000,000 ordinary fully paid shares at an issue price of 10 cents per share.

Settlement of the first tranche of the share placement of \$2,030,000 is expected to occur on 11 September 2013.

The second tranche of the placement comprises 479,700,000 shares at 10 cents per share for gross proceeds of \$47,970,000 and is subject to the approval of shareholders of the Company. A notice convening a meeting of shareholders is currently being prepared.

Existing shareholders dominated the subscriptions. New investors included significant funds domiciled in Australia, Hong Kong and the United Kingdom. The placement was completed by Petra Capital Limited acting as exclusive lead manager and book runner.

A further \$10,000,000 is proposed to be raised through a Share Purchase Plan (SPP) offer to eligible shareholders also at 10 cents per share with the directors reserving the right to accept oversubscriptions of up to a further \$5,000,000. The record date for the SPP is 4 September 2013. Key dates in respect of the SPP will be outlined in the SPP offer document to be sent to shareholders with the notice of general meeting seeking shareholder approval for completion of the second tranche of the placement and the SPP.

Steve Norregaard Managing Director